First Alzheimer’s commercial blood test to detect amyloid beta hits the market
A new blood test that detects the presence of Alzheimer’s brain plaques on Thursday became the first to hit the commercial market on a wide scale.
A new blood test that detects the presence of Alzheimer’s brain plaques on Thursday became the first to hit the commercial market on a wide scale.
The experimental blood test rivals the accuracy of standard diagnostic methods and may soon prove to be a cost-effective, accessible tool in the clinical setting, according to some in the scientific community.
Screen dementia patients for pain at every visit: new guidance from APA, AAN … New palliative medicine journal for clinicians launching in spring 2020 … U.S. hospitals harnessing resources to brace for any spike in coronavirus cases … Blood-based diagnostic sensor helps to accurately detect Alzheimer’s disease
A blood test that helps to detect early Alzheimer’s disease is one step closer to clinical use. Its accuracy and low cost are game changers, researchers say.
A path to quicker and easier diagnosis seems near. Blood tests have the potential to replace costly and intrusive diagnostics.
A blood test to detect Alzheimer’s disease may reduce the need for more costly, specialized and invasive diagnostic procedures.
Alzheimer’s researchers are getting closer to marketing tests that can assist in early diagnosis of this deadly form of dementia and assess risk factors for memory loss.